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Abstract 
Many ionizable drugs are developed and marketed as salt forms. However, there are no clear US 
regulatory guidelines on drug strength labeling for salts. The strengths of some drugs are expressed as 
salts and some as free acids/bases. This study surveyed the top 200 US drugs to assess the common 
practice in industry. The top 200 drugs prescribed in the United States were included in this survey. The 
drugs containing active pharmaceutical ingredient (API) salts were selected for analysis. Generic or 
combination products with redundant API salts were excluded. The package insert of each selected drug 
was reviewed, and the information on drug strength expression was extracted and categorized. Out of the 
top 200 drugs, 59 unique API salts were identified. The drug strengths were expressed as salts for 32 
drugs (54%) and as free acids/bases for 27 drugs (46%). The survey results revealed the inconsistent 
practice among the industries regarding the drug strength expression for salts. Non-harmonized labeling 
practice can lead to confusions, potential calculation/dosing errors, and complications in labeling new 
products. The authors recommend the US Food and Drug Administration to standardize the labeling 
format for salts and preferably express the drug strengths based on the free acid/base forms. © 2011 
Wiley Periodicals, Inc. and the American Pharmacists Association. 
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Purpose. Many ionizable drugs are developed and marketed as salt forms. However, 
there are no clear US regulatory guidelines on drug strength labeling for salts. The 
strengths of some drugs are expressed as salts and some as free acids/bases. This study 
surveyed the top 200 US drugs to assess the common practice in industry. 
Methods. The top 200 drugs prescribed in US were included in this survey. The drugs 
containing API salts were selected for analysis. Generic or combination products with 
redundant API salts were excluded. The package insert of each selected drug was 
reviewed, and the information on the drug strength expression was extracted and 
categorized.  
Results. Out of the top 200 drugs, 59 unique API salts were identified. The drug 
strengths were expressed as salts for 32 drugs (54%) and as free acids/bases for 27 drugs 
(46%). 
Conclusion. The survey results revealed the inconsistent practice among the industry 
regarding the drug strength expression for salts. Non-harmonized labeling practice can 
lead to confusions, potential calculation/dosing errors, and complications in labeling new 
products. The authors recommend the FDA and industry to standardize the labeling 









Many drug molecules are weak acids or bases, and they can form stable salts with 
the suitable counter ions [1-2]. For various reasons, the salt forms are often chosen as the 
API (active pharmaceutical ingredient) forms for the development and commercialization 
of the drug products [1-2]. Based on a recent study, 51.4% of the 1356 drugs in the US 
Orange Book Database are formulated with the salt forms [3]. 
Currently, the US labeling requirements for drug products do NOT specify how 
the drug strengths are expressed for salt forms, as evidenced by the relevant sections from 
the Code of Federal Regulations (CFR) and United States Pharmacopoeia (USP) below.  
Excerpts from CFR [4] 
 
(a)(2) Drug names, dosage form, route of administration, and 
controlled substance symbol. The proprietary name and the established 
name of the drug, if any, as defined in section 502(e)(3) of the Federal 
Food, Drug, and Cosmetic Act (the act) or, for biological products, the 
proper name (as defined in §600.3 of this chapter) including any 
appropriate descriptors. This information must be followed by the 
drug's dosage form and route of administration. 
 
(a)(8) Dosage forms and strengths. A concise summary of the 
information required under paragraph (c)(4) of this section, with any 
appropriate subheadings (e.g., tablets, capsules, injectable, suspension), 
including the strength or potency of the dosage form in metric system 
(e.g., 10-milligram tablets) and whether the product is scored. 
 
(c)(4)3 Dosage forms and strengths. This section must contain 
information on the available dosage forms to which the labeling applies 
and for which the manufacturer or distributor is responsible, including: 
(i) The strength or potency of the dosage form in metric system (e.g., 
10 milligram tablets), and, if the apothecary system is used, a statement 
of the strength in parentheses after the metric designation; and 
(ii) A description of the identifying characteristics of the dosage forms, 
including shape, color, coating, scoring, and imprinting, when 
applicable. The National Drug Code number(s) for the drug product 
must not be included in this section. 
 
Excerpt from USP [5] 
10.40.10 Amount of Ingredient Per Dosage Unit 
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The strength of a drug product is expressed on the container label in 
terms of micrograms or milligrams or grams or percentage on the 
therapeutically active moiety or drug substance, whichever form is used 
in the title, unless otherwise indicated in an individual monograph. 
Both the active moiety and drug substance names and their equivalent 
amounts are then provided in the labeling.  
 
As a result, the strengths of some drugs are expressed as the salt forms and some 
as the free bases/acids. In other words, it is not possible for anyone to accurately interpret 
the strength of a salt drug simply based on the drug product title and the strength. To 
obtain such information, one has to read the “Description” section of the FDA-approved 
drug labeling which is also known as the “package insert” and will be referred as such 
throughout the rest of this article. In the Description section, the manufacturer typically 
provides some clarification on the strength expression of the salt. Alternatively, this 
information can be searched for in the Orange Book [6] or the Drugs@FDA database [7]. 
However, these publications do not accompany the drug products, and most users are not 
aware of this feature. 
In 2006, FDA amended its regulations governing the content and format of the 
package insert [8]. The changes were intended to make it easier for the health care 
practitioners to access, read, and use the prescribing information. However, the strength 
expression issue mentioned above was not addressed. To make matters worse, the 
Description section was moved from the beginning of the document to the middle, 
making it more difficult for an average user to obtain the information needed to interpret 
the drug strengths correctly.  
Non-harmonized labeling practice can lead to unnecessary confusion and 
mistakes among pharmaceutical scientists and health care practitioners. This study was 
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initiated in order to survey the current practice in pharmaceutical industry regarding the 
strength expression for drugs which are marketed in their salt forms. 
 
METHODS 
This survey included the top 200 drugs in the US market based on the number of 
prescriptions dispensed in 2010 [9]. The package inserts of all 200 drugs were obtained 
from DailyMed [10] for analysis. The drugs which did not contain API salt forms were 
first eliminated. Potassium chloride products, quaternary ammonium salts, and proteins 
were also excluded. The remaining drugs were then sorted to remove duplication. Multi-
source generic products containing the same API salt were counted as one entry; only the 
highest ranking product was included in the data table. Combination drug products were 
included if they contain at least one API salt which was not present as a single drug 
product in the top 200 list. For example, hydrocodone/APAP was included, because 
hydrocodone (bitartrate salt) was not available as a single drug product. Amlodipine 
besylate/benazepril, on the other hand, was not included, because each of the two API 
salts was available as a single drug product in the top 200 list. Hydrocodone bitartrate and 
codeine phosphate were present in several different combination products, and only the 
highest ranking product for each drug was included in the data table. 
Once the non-salt and duplicate drugs were eliminated, the remaining drugs were 
categorized into two groups: salts of weak acids and salts of weak bases. The Description 
section of the package insert of each drug was carefully reviewed to identify whether the 




 The survey results are summarized in Figure 1. Out of the top 200 drugs 
prescribed in 2010, 59 unique API salts were identified. Thirteen of the 59 drugs were 
salts of acids; the drug strengths were expressed as the free acids for 7 drugs and as the 
salts for 6 drugs. Forty-six drugs of the 59 drugs were salts of bases; the drug strengths 
were expressed as the free bases for 20 drugs and as the salts for 26 drugs. The data on 
the 59 individual drugs are presented in Tables 1 and 2 for acidic and basic drugs, 
respectively. Overall, 54% products were labeled based on the salt forms and 46% based 
on free acid/base forms. 
In addition to the percent distributions, three noteworthy observations are 
included below.  
Amlodipine besylate/benazepril hydrochloride was a combination capsule product 
(rank 136). The capsule strengths were expressed as the free base for amlodipine besylate 
but as the salt for benazepril hydrochloride [10].  
In the package insert of rosuvastatin calcium tablet (rank 16), it was not explained 
whether the tablet strengths were expressed as the salt or the free acid [10]. Additional 
information was obtained from the Drugs@FDA database [7], which verified that the 
tablet strengths were expressed as the salt.  
An error was noted in TEVA’s package insert of benazepril hydrochloride (rank 
174), a generic product of Lotensin® from Novartis. The excerpts from the two package 
inserts are shown below for comparison [10]. The term “hydrochloride” was apparently 




Excerpt from TEVA’s Package Insert: 
Benazepril hydrochloride is supplied as tablets containing 5 mg, 10 mg, 20 mg, 
and 40 mg of benazepril for oral administration. 
 
 
Excerpt from Novartis’s Package Insert: 
Lotensin is supplied as tablets containing 5 mg, 10 mg, 20 mg and 40 mg of 




The molecular formula of a salt is different from that of the free acid/base due to 
the presence of the counter ion. In some cases, the counter ion can account for a 
significant fraction of the total formula weight.  For example, escitalopram is marketed as 
the oxalate salt [10]. The MW of escitalopram (free base) is 324, and the MW of 
escitalopram oxalate is 414. The counter ion in this case is 21.7% of the salt. Fentanyl 
citrate (not in top 200 list) represents an extreme case, where the citrate ion accounts for 
36.3% of the total salt weight. 
Currently, the US regulatory labeling requirements do not specify how the 
strengths are labeled for drugs which are salts. The manufacturer can express the drug 
strength as the salt form or as free acid/base. If the manufacturer chooses to express the 
strength as the salt form, it is implied that the active moiety content is the labeled strength 
multiplied by the weight fraction of the drug in the salt form. For example, the package 
insert of metoprolol tartrate [10] states:  
Metoprolol tartrate USP, is a selective beta1-adrenoreceptor blocking 
agent, available as 50- and 100-mg tablets for oral administration… 
Metoprolol tartrate USP is (±)-1-(Isopropylamino)-3-[p-(2-
methoxyethyl)phenoxy]-2-propanol L-(+)-tartrate (2:1) salt… 
Metoprolol tartrate USP is a white, practically odorless, crystalline 
powder with a molecular weight of 684.82. 
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In this case, the MW of metoprolol (free base) is 267 (not given in the package insert). 
The free base weight fraction is calculated to be 78.0%. Therefore, a 100 mg strength 
metoprolol tartrate tablet contains only 78 mg metoprolol.  
If the manufacturer expresses the strength as the free base/acid form, the 
equivalent strength terms are described explicitly in the package insert. Below is an 
example from the escitalopram oxalate package insert [10]:  
The molecular formula is C20H21FN2O•C2H2O4 and the 
molecular weight is 414.40. Lexapro® tablets are film-coated, 
round tablets containing escitalopram oxalate in strengths 
equivalent to 5 mg, 10 mg, and 20 mg escitalopram base. 
 
Based on the survey data of the top 200 US drugs described in the Results section, 
there is no clear trend or consensus among industry regarding the strength labeling for 
salts. About 54% of the salt drugs are labeled as salts and the remaining as free 
acids/bases. This inconsistent labeling practice can lead to confusion among 
pharmaceutical scientists and health care practitioners.  
The misinterpretation of the salt vs. free forms can lead to calculation errors, 
which can impact many critical activities. For example, the strengths of all escitalopram 
oxalate products are expressed as the free base [10]. If a pharmacist uses the escitalopram 
oxalate drug substance to compound 15 mg strength capsules, he will need 19 mg 
escitalopram oxalate per capsule. However, if the pharmacist misinterprets the strength 
expression as the salt, he will use only 15 mg escitalopram oxalate per capsule, and the 
final capsule strength will be 21.7% sub-potent. A similar error can occur if an analytical 
scientist uses the escitalopram oxalate material to prepare a standard solution without 
adjusting the calculations to account for the weight of the oxalate.   
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 Non-harmonized labeling practice of the salts among industry can also complicate 
the strength labeling of new products based on alternative forms or combinations of 
existing drugs. Two examples are discussed below. 
 Metoprolol was first developed and marketed as a tartrate salt. The strengths of 
the metoprolol tartrate products (tablets and iv injections) were labeled based on the salt 
[10]. The metoprolol succinate salt was later developed as the API form for the extended 
release oral tablets. Due to the pre-existing tablet strengths based on the tartrate salt form, 
the new metoprolol succinate tablets were labeled based on the tartrate salt to maintain 
consistency (see excerpt from package insert [10] below).  
Metoprolol succinate extended-release tablets are a beta1-
selective (cardioselective) adrenoceptor blocking agent, for oral 
administration, available as extended release tablets... The 
tablets contain 23.75 mg, 47.50 mg, 95 mg and 190 mg of 
metoprolol succinate equivalent to 25 mg, 50 mg, 100 mg and 
200 mg of metoprolol tartrate USP, respectively. 
 
It is perplexing that the strength of a metoprolol succinate tablet does not reflect the 
quantity of metoprolol succinate in the tablet but rather the equivalent quantity of 
metoprolol tartrate. In other words, a 25 mg metoprolol succinate tablet contains only 
23.75 mg metoprolol succinate which is equivalent to 25 mg metoprolol tartrate. This 
confusing situation could have been avoided if the strengths of the original metoprolol 
tartrate tablets had been labeled based on the free base.  
The second example involves amlodipine besylate and benazepril hydrochloride. 
Both drugs were initially marketed as individual oral tablet products. The amlodipine 
besylate tablets were labeled based on the free base [10], and the benazepril 
hydrochloride tablets were labeled based on the salt [10]. The combination products of 
these two drugs were later developed and marketed. Due to the pre-existing single drug 
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products, the strengths of the combo capsules were expressed as the free base for 
amlodipine besylate and as the salt for benazepril HCl (see excerpt from package insert 
[10] below). 
Amlodipine besylate and benazepril hydrochloride capsules are 
a combination of amlodipine besylate and benazepril 
hydrochloride. The capsules are formulated in six different 
strengths for oral administration with a combination of 
amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of 
amlodipine, with 10 mg, 20 mg or 40 mg of benazepril 
hydrochloride providing for the following available 
combinations: 2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg 
and 10/40 mg.  
 
 Based on the issues and examples described above, it should become evident that 
a more consistent strength labeling practice should be promoted for pharmaceutical salts 
to avoid unnecessary confusion and errors. The authors recommend the approach to 
express the strengths of salts based on the free acid/base forms. This approach states the 
exact quantity of the active moiety of the drug in the dosage form. It eliminates potential 
labeling issues when new forms of the same drug are developed and marketed at a later 
date.  
 It is also worthwhile to emphasize that while this survey focused only on the 
marketed drug products, the recommendation above needs to be implemented for clinical 
trial materials to achieve the desired outcomes for future marketed products. 
 Even with a standardized labeling approach, scientists and pharmacists still need 
to understand the relationship between salts and their free base/acid forms to perform 
calculations accurately for sample/dosage preparations. Therefore, it is important to 
provide the necessary training to entry level scientists and pharmacists. In addition, it is 
recommended that the manufacturers describe the strengths for both the salt and free 
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acid/base forms in the package insert to avoid any potential confusion. For example, 
clopidogrel bisulfate (Plavix®) is marketed as 75 and 300 mg strengths tablets. Even 
though the strengths are expressed as the free base, the package insert [10] states the 
strengths for both the salt and the free base without ambiguity:  
Plavix for oral administration is provided as either pink, round, 
biconvex, debossed, film-coated tablets containing 97.875 mg of 
clopidogrel bisulfate which is the molar equivalent of 75 mg of 
clopidogrel base or pink, oblong, debossed film-coated tablets 
containing 391.5 mg of clopidogrel bisulfate which is the molar 




 A survey of the top 200 US drugs revealed the inconsistent practice of strength 
expression for drugs which were marketed as salts. The strengths were expressed as the 
salt forms for 54% drugs and as the free acid/base forms for the remaining 46% drugs. 
Non-harmonized labeling practice can lead to unnecessary confusion among 
pharmaceutical scientists and healthcare practitioners. The confusion on drug strengths 
and forms can result in potential errors in calculations and dosing, especially when the 
drugs are to be compounded extemporaneously prior to use. This inconsistent labeling 
practice can also complicate the strength labeling when new products of existing drugs 
are developed, such as new salts and combination products. The authors recommend the 
FDA and industry to standardize the labeling format for salts and preferably express the 
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Figure 1. Summary results of top 200 drugs to assess the current industry practice of 




Table 1. Drug strength expressions for salts of acidic drugs from the top 200 list. 
 
Rank a Drug b Strength Expression As 
4 Atorvastatin Calcium free acid 
5 Levothyroxine Sodium salt form 
9 Esomeprazole Magnesium free acid 
10 Montelukast Sodium free acid 
16 Rosuvastatin Calcium salt form 





53 Pravastatin Sodium salt form 
75 Alendronate Sodium free acid 
115 Penicillin V Potassium free acid 
142 Risedronate Sodium salt form 
152 Pantoprazole Sodium free acid 
187 Naproxen salt form 
 
a. The ranking information was obtained from Reference 9. 
b. Some API salts were used in several generic or combination products. Only the highest 
ranking product was included for each API salt.
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Table 2. Drug strength expressions for salts of basic drugs from the top 200 list. 
 
Rank a Drug b Strength Expression As  
1 Hydrocodone/APAP salt form 
8 Clopidogrel Bisulfate free base 
11 Metoprolol Tartrate  salt form 
13 Escitalopram Oxalate free base 
18 Albuterol Sulfate free base 
19 Metformin HCl  salt form 
20 Sertraline HCl free base 
22 Metoprolol Succinate salt form (as tartrate salt) 
24 Zolpidem Tartrate salt form 
25 
Fluticasone propionate/ 
Salmeterol xinafoate  
free base 
29 Trazodone HCl salt form 
33 Tramadol HCl  salt form 
35 Duloxetine Hydrochloride free base 
37 Amlodipine Besylate free base 
42 Quetiapine Fumarate free base 
43 Promethazine HCl salt form 
52 Pioglitazone free base 
56 Fluoxetine HCl free base 
64 Donepazil Hydrochloride salt form 
66 APAP/Codeine  salt form 
70 Ciprofloxacin HCl free base 
77 Venlafaxine Hydrochloride free base 
79 Sildenafil Citrate free base 
83 Citalopram Hydrobromide free base 
93 Cyclobenzaprine HCl salt form 
95 Methylphenidate HCl  salt form 
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96 Fexofenadine HCl salt form 
98 Propoxyphene-N/APAP salt form 
104 Memantine Hydrochloride salt form 
118 Sitagliptin Phosphate  free base 
120 Amitriptyline Hydrochloride salt form 
121 Clonidine Hydrochloride salt form 
125 Lisdexamfetamine Dimesylate salt form 
128 Oxycodone Hydrochloride salt form 
150 Doxycycline Hyclate free base 
157 Tamsulosin Hydrochloride salt form 
161 Paroxetine Hydrochloride free base 
163 
Buprenorphine Hydrochloride / 
Naloxone Hydrochloride 
free base (both actives) 
165 Enalapril Maleate salt form 
174 Benazepril Hydrochloride salt form 
175 Olanzapine Pamoate  free base 
179 Tolterodine Tartrate  salt form 
183 Amphetamine Salts salt form 
188 Ranitidine Hydrochloride free base 
191 Diltiazem Hydrochloride salt form 
197 Verapamil Hydrochloride SR salt form 
 
a. The ranking information was obtained from Reference 9. 
b. Some API salts were used in several generic or combination products. Only the highest ranking 
product was included for each API salt. 
